PXMTFPHAXIAM Therapeutics S.A

About PHAXIAM Therapeutics S.A (PXMTF)

PHAXIAM Therapeutics S.A (PXMTF) is a N/A company headquartered in Lyon, France whose shares trade over-the-counter on the Pink tier.

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.

PXMTF key facts

Ticker symbol

PXMTF

Market tier

Pink

Headquarters

Lyon, France

Country of incorporation

FR

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Explore more: Pink stocks · OTC stocks starting with P